BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Statement By Sanofi-Aventis (France) (SASY.PA)


10/19/2005 5:12:27 PM

PARIS, Jan. 19 /PRNewswire-FirstCall/ -- Rhodia announced today that it has commenced legal proceedings in the United States of America and Brazil against sanofi-aventis as former owner or operator of the Silver Bow (United States of America) and Cubatao (Brazil) sites to seek to obtain compensation for environmental liabilities related to these two sites.

Aventis and Rhodia signed a final settlement agreement on March 27, 2003 pursuant to which the two companies settled all claims in connection with the Environmental Indemnification Agreement signed by Aventis and Rhodia in 1998. Pursuant to this settlement agreement, which was publicly disclosed, Aventis made a final payment to Rhodia in 2004.

As a result of the settlement agreement, sanofi-aventis considers that the matter is closed and intends to vigorously defend its position in any legal proceedings.

About sanofi-aventis

Sanofi-aventis is the world's 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York .

CONTACT: Jean-Marc Podvin Vice President, Media Relations sanofi-aventis +331-53-77-4223 Charles F. Rouse III sanofi-aventis 908-243-6050

sanofi-aventis

CONTACT: Jean-Marc Podvin, Vice President, Media Relations,sanofi-aventis, +331-53-77-4223, or Charles F. Rouse III of sanofi-aventis,+1-908-243-6050



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES